全球生物製劑契約製造市場規模、佔有率、趨勢和成長分析報告（2026-2034）

預計生物製劑契約製造市場將從 2025 年的 387.7 億美元成長到 2034 年的 957 億美元，2026 年至 2034 年的複合年成長率為 10.56%。

隨著製藥和生物技術公司擴大將生產外包給專業的契約製造生產商，全球生物製藥契約製造市場正經歷強勁成長。對包括單株抗體和疫苗在內的生物製藥的需求不斷成長，推動了對先進生產能力的需求。契約製造組織（CMO）憑藉其成本效益、技術專長和可擴展的生產能力，成為製藥研發公司的理想合作夥伴。生物製藥和生物相似藥研發的進展進一步促進了市場擴張。

關鍵促進因素包括生物製藥日益複雜、監管合規要求以及內部生產設施高成本。外包使企業能夠利用外部生產專業知識，從而專注於研發和商業化。慢性病激增和生物療法產品線的擴展也推動了市場需求。策略聯盟、併購和設施擴建是塑造該市場競爭格局的常見趨勢。

生物製劑契約製造市場的未來前景依然十分光明。細胞培養技術、一次性使用系統和製程最佳化的持續進步可望提高效率和產量。生物相似藥和個人化生物療法的日益普及將進一步推動市場需求。隨著全球醫療保健需求的不斷變化，契約製造生產商有望在及時、經濟高效地提供複雜生物製劑方面發揮越來越重要的作用。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球生物製劑契約製造市場：依產品分類

• 市場分析、洞察與預測
• 單株抗體（mAbs）
• 重組蛋白
• 疫苗
• 反義寡核苷酸、RNA干擾與分子療法
• 其他

第5章：全球生物製劑契約製造市場：依適應症分類

• 市場分析、洞察與預測
• 腫瘤學
• 自體免疫疾病
• 感染疾病
• 心血管疾病
• 代謝性疾病
• 神經病學
• 其他

第6章 全球生物製品契約製造市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第7章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第8章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Wuxi Biologics
  • Fujifilm Diosynth Biotechnologies
  • Boehringer Ingelheim International GmbH
  • Lonza
  • Samsung Biologics
  • AbbVie Inc
  • Catalent
  • Bioreliance（Merck KGaA）
  • Thermo Fisher Scientific Inc
  • Eurofins Scientific

The Biologics Contract Manufacturing Market size is expected to reach USD 95.70 Billion in 2034 from USD 38.77 Billion (2025) growing at a CAGR of 10.56% during 2026-2034.

The Global Biologics Contract Manufacturing Market is experiencing strong growth as pharmaceutical and biotechnology companies increasingly outsource production to specialized contract manufacturers. The rising demand for biologic drugs, including monoclonal antibodies and vaccines, is driving the need for advanced manufacturing capabilities. Contract manufacturing organizations offer cost efficiency, technical expertise, and scalable production, making them attractive partners for drug developers. Growing research in biologics and biosimilars is further strengthening market expansion.

Key drivers include the increasing complexity of biologic products, the need for regulatory compliance, and the high cost of in-house manufacturing facilities. Outsourcing allows companies to focus on research and commercialization while leveraging external expertise for production. The surge in chronic diseases and the growing pipeline of biologic therapies are also contributing to demand. Strategic collaborations, mergers, and facility expansions are common trends shaping the competitive landscape of this market.

Future prospects for the biologics contract manufacturing market remain highly promising. Continuous advancements in cell culture technologies, single-use systems, and process optimization are expected to enhance efficiency and output. The rising adoption of biosimilars and personalized biologic therapies will further drive demand. As global healthcare needs evolve, contract manufacturers are likely to play an increasingly vital role in ensuring the timely and cost-effective delivery of complex biologic medicines.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Monoclonal Antibodies (mAbs)
• Recombinant Proteins
• Vaccines
• Antisense, RNAi, & Molecular Therapy
• Others

By Indication

• Oncology
• Autoimmune Diseases
• Infectious Diseases
• Cardiovascular Diseases
• Metabolic Diseases
• Neurology
• Others

COMPANIES PROFILED

• Wuxi Biologics, Fujifilm Diosynth Biotechnologies, Boehringer Ingelheim International GmbH, Lonza, Samsung Biologics, AbbVie Inc, Catalent, Bioreliance Merck KGaA, Thermo Fisher Scientific Inc, Eurofins Scientific
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Monoclonal Antibodies (mAbs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Recombinant Proteins Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Antisense, RNAi, & Molecular Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Autoimmune Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Cardiovascular Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Metabolic Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Neurology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Product
  • 6.2.2 By Indication
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Product
  • 6.3.2 By Indication
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Product
  • 6.4.2 By Indication
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Product
  • 6.5.2 By Indication
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Product
  • 6.6.2 By Indication
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL BIOLOGICS CONTRACT MANUFACTURING INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Wuxi Biologics
  • 8.2.2 Fujifilm Diosynth Biotechnologies
  • 8.2.3 Boehringer Ingelheim International GmbH
  • 8.2.4 Lonza
  • 8.2.5 Samsung Biologics
  • 8.2.6 AbbVie Inc
  • 8.2.7 Catalent
  • 8.2.8 Bioreliance (Merck KGaA)
  • 8.2.9 Thermo Fisher Scientific Inc
  • 8.2.10 Eurofins Scientific